Headache

Article	Citations
Headaches Associated With Personal Protective Equipment – A Cross‐Sectional Study Among Frontline Healthcare Workers During COVID‐19	313
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice	275
COVID‐19 is a Real Headache!	176
The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic‐specific estimates from government health surveys	120
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review	93
The Role of Diet and Nutrition in Migraine Triggers and Treatment: A Systematic Literature Review	83
Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine	82
Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers	78
Headaches During COVID‐19: My Clinical Case and Review of the Literature	70
Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study	70
Headache as a Cardinal Symptom of Coronavirus Disease 2019: A Cross‐Sectional Study	62
Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study	61
Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?	57
Hypertension: A new safety risk for patients treated with erenumab	56
High Prevalence of Headaches During Covid‐19 Infection: A Retrospective Cohort Study	56
Spectrum of Headaches Associated With SARS‐CoV‐2 Infection: Study of Healthcare Professionals	55
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2	54
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine	53
COVID‐19 and Headache: A Primer for Trainees	53
Case Series of Headache Characteristics in COVID‐19: Headache Can Be an Isolated Symptom	52
Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study	49
Chronic versus episodic migraine: The 15‐day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency	46
Persistent Headache and Persistent Anosmia Associated With COVID‐19	44
Migraine and Ischemic Stroke in Women. A Narrative Review	44
Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta‐Analysis	42

Frequency and Type of Red Flags in Patients With Covid‐19 and Headache: A Series of 104 Hospitalized Patients	42
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study	40
Headache associated with COVID‐19: Epidemiology, characteristics, pathophysiology, and management	40
Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study	40
The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study	40
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients	40
Toward a better understanding of persistent headache after mild COVID‐19: Three migraine‐like yet distinct scenarios	39
Alterations in Brain Function After Cognitive Behavioral Therapy for Migraine in Children and Adolescents	38
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1	37
Headache attributed to idiopathic intracranial hypertension and persistent post‐idiopathic intracranial hypertension headache: A narrative review	37
Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire	35
Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study	35
Erenumab in Chronic Migraine: An Australian Experience	34
Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients	33
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing	33
Remote electrical neuromodulation for acute treatment of migraine in adolescents	33
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial	32
Erenumab for headaches in idiopathic intracranial hypertension: A prospective open‐label evaluation	32
Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta‐analysis	32
Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study	31
A link between gastrointestinal disorders and migraine: Insights into the gut–brain connection	30
Headache characteristics and burden from chronic migraine with medication overuse headache: Cross‐sectional observations from the Medication Overuse Treatment Strategy trial	29
Neck pain associated with migraine does not necessarily reflect cervical musculoskeletal dysfunction	29
Smartphone‐Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial	27
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study	27
Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case‐Control and Case‐Crossover Settings: A Systematic Review and Meta‐Analysis	27
Systematic review of outcomes and endpoints in preventive migraine clinical trials	27
Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data	26
Headache in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Narrative Review	26
Cognitive Networks Disarrangement in Patients With Migraine Predicts Cutaneous Allodynia	26
Systematic review of outcomes and endpoints in acute migraine clinical trials	25
Real‐world efficacy, tolerability, and safety of ubrogepant	25
Trigeminal neuralgia as the sole neurological manifestation of COVID‐19: A case report	25
Migraine as a Cortical Brain Disorder	25
Patient experience of telemedicine for headache care during the COVID‐19 pandemic: An American Migraine Foundation survey study	25
Spontaneous spinal cerebrospinal fluid‐venous fistulas in patients with orthostatic headaches and normal conventional brain and spine imaging	24
Learning the full impact of migraine through patient voices: A qualitative study	24
Headache in transgender and gender‐diverse patients: A narrative review	24
United States Patients’ Perspective of Living With Migraine: Country‐Specific Results From the Global “My Migraine Voice” Survey	23
Impact of Depression and Anxiety Symptoms on Patient‐Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR)	22
Management of primary headaches during pregnancy, postpartum, and breastfeeding: A systematic review	22
Serum Homocysteine, Pyridoxine, Folate, and Vitamin B12 Levels in Migraine: Systematic Review and Meta‐Analysis	22
63rd Annual Scientific Meeting American Headache Society®	22
Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: A narrative review	22
Cranial Autonomic Symptoms of Migraine in Japan: Prospective Study of 373 Migraine Patients at a Tertiary Headache Center	22
Dietary magnesium and migraine in adults: A cross‐sectional analysis of the National Health and Nutrition Examination Survey 2001–2004	21
Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patien	21
Cyclic vomiting syndrome: A narrative review and guide to management	21
Indomethacin‐responsive headaches—A narrative review	21
Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT‐6) Total and Item‐Specific Scores in Chronic Migraine	21

Could CGRP Antagonists Be Helpful in the Fight Against COVID‐19?	21
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAI	21
Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome	21
Alterations in Functional Connectivity During Different Phases of the Triggered Migraine Attack	20
Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients	20
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache	20
Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR study	19
No “Wearing‐Off Effect” Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long‐Term Study	19
Risk Factors for the Development of Post‐Traumatic Headache Attributed to Traumatic Brain Injury: A Systematic Review	19
Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation	18
Early impact of the COVID‐19 pandemic on outpatient migraine care in Hawaii: Results of a quality improvement survey	18
Green Flags and headache: A concept study using the Delphi method	18
Trigeminal Neuralgia Crisis – Intravenous Phenytoin as Acute Rescue Treatment	18
The Stereotypical Image of a Person With Migraine According to Mass Media	18
The changing face of trigeminal neuralgia—A narrative review	18
What are Headache Smartphone Application (App) Users Actually Looking for in Apps: A Qualitative Analysis of App Reviews to Determine a Patient Centered Approach to Headache Smartphone Apps	18
A Randomized, Double‐Dummy, Emergency Department‐Based Study of Greater Occipital Nerve Block With Bupivacaine vs Intravenous Metoclopramide for Treatment of Migraine	17
Delay in OnabotulinumtoxinA Treatment During the COVID‐19 Pandemic‐Perspectives from a Virus Hotspot	17
Headache education by leaflet distribution during COVID‐19 vaccination and school‐based on‐demand e‐learning: Itoigawa Geopark Headache Awareness Campaign	17
Serum lipid abnormalities in migraine: A meta‐analysis of observational studies	17
Headache as the Presenting Symptom in 2 Patients With COVID‐19 and a History of Migraine: 2 Case Reports	17
Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real‐World Case Series	16
Are Migraine Patients at Increased Risk for Symptomatic Coronavirus Disease 2019 Due to Shared Comorbidities?	16
Prevalence and association of lifestyle and medical‐, psychiatric‐, and pain‐related comorbidities in patients with migraine: A cross‐sectional study	16
Wake‐Up Headache Is Associated With Sleep Bruxism	16
COVID‐19 and Headache Medicine: A Narrative Review of Non‐Steroidal Anti‐Inflammatory Drug (NSAID) and Corticosteroid Use	16
Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial	16
Trigeminal and cervical sensitization during the four phases of the migraine cycle in patients with episodic migraine	15
Psychometric validation and meaningful within‐patient change of the Migraine‐Specific Quality of Life questionnaire version 2.1 electronic patient‐reported outcome in patients with episodic and chroni	15
A non‐convulsant delta‐opioid receptor agonist, KNT‐127, reduces cortical spreading depression and nitroglycerin‐induced allodynia	15
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis	15
Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)—A multinational observational study	15
Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans	15
Telehealth as a new care delivery model: The headache provider experience	15
Evidence that blood–CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen	14
Migraine in the Time of COVID‐19	14
Normal glymphatic system function in patients with migraine: A pilot study	14
Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans	14
The endocannabinoid system and related lipids as potential targets for the treatment of migraine‐related pain	14
Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial	14
What Will it Take to Move the Needle for Headache Disorders? An Advocacy Perspective	14
Patterns of Perceived Stress Throughout the Migraine Cycle: A Longitudinal Cohort Study Using Daily Prospective Diary Data	14
The intersection of COVID‐19, school, and headaches: Problems and solutions	14
Gepants	13
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice	13
Migraine and light: A narrative review	13
Migraine and Sport in a Physically Active Population of Students: Results of a Cross‐Sectional Study	13
Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine	13
A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond	13
Telehealth perceptions and utilization for the delivery of headache care before and during the COVID‐19 pandemic: A mixed‐methods study	13
Preference for Lighting Chromaticity in Migraine With Aura	13
Primary headaches among gender dysphoric female‐to‐male individuals: A cross‐sectional survey on gender transition experience	13
Triggers of Primary Headaches: Issues and Pathways Forward	13
Impact of abuse on migraine‐related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research	13
A Real‐World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment	13
Alterations in the structure and function of the brain in adolescents with new daily persistent headache: A pilot MRI study	13
Diagnostic accuracy of an artificial intelligence online engine in migraine: A multi‐center study	13
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study	13
Validity and reliability of the self‐administered Visual Aura Rating Scale questionnaire for migraine with aura diagnosis: A prospective clinic‐based study	12
Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine	12
STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acu	12
Migraine diagnosis and treatment: A knowledge and needs assessment of women’s healthcare providers	12
Perceived stress and pain severity in individuals with chronic migraine: A longitudinal cohort study using daily prospective diary data	12
Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial	12
E‐Consultation in Headache Medicine: A Quality Improvement Pilot Study	12
Clinical features of new daily persistent headache: A retrospective chart review of 328 cases	12
Objectively Measured Physical Activity in Migraine as a Function of Headache Activity	12
The current state of headache medicine education in the United States and Canada: An observational, survey‐based study of neurology clerkship directors and curriculum deans	12
Osmophobia and Odor‐Triggered Headaches in Children and Adolescents: Prevalence, Associated Factors, and Importance in the Diagnosis of Migraine	12
Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger Exposures	12
Employee and Employer Benefits From a Migraine Management Program: Disease Outcomes and Cost Analysis	12
Arachnoiditis, a complication of epidural blood patch for the treatment of low‐pressure headache: A case report and systematic review	12
Cluster headache epidemiology including pediatric onset, sex, and ICHD criteria: Results from the International Cluster Headache Questionnaire	12
The Effect of Adding Calcitonin Gene‐Related Peptide Monoclonal Antibodies to Onabotulinum Toxin A Therapy on Headache Burden: A Retrospective Observational Case Series	12
Stimulation of Posterior Thalamic Nuclei Induces Photophobic Behavior in Mice	12
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response	11
Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks	11
Measurement properties of the Headache Impact Test (HIT‐6™ Brazil) in primary and secondary headaches	11
A new hypothesis linking oxytocin to menstrual migraine	11
Baseline sleep quality, stress, and depressive symptoms, and subsequent headache occurrence in a six‐week prospective cohort study of patients with episodic migraine	11

Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary	11
The relationship of headache as a symptom to COVID‐19 survival: A systematic review and meta‐analysis of survival of 43,169 inpatients with COVID‐19	11
Headache as a COVID‐19 onset symptom and post‐COVID‐19 symptom in hospitalized COVID‐19 survivors infected with the Wuhan, Alpha, or Delta SARS‐CoV‐2 varian	11
Allodynia and Disability in Migraine: The Mediating Role of Stress	11
Narrative review of peripheral nerve blocks for the management of headache	11
Digital Therapeutic Self‐Management Intervention in Adolescents With Migraine: Feasibility and Preliminary Efficacy of “Migraine Manager”	11
Calcitonin Gene‐Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta‐Analysis	11
Dietary zinc intake and migraine in adults: a cross‐sectional analysis of the National Health and Nutrition Examination Survey 1999–2004	11
Wear‐Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries	11
Erenumab patient characteristics, medication adherence, and treatment patterns in the United States	11
Prolactin signaling modulates stress‐induced behavioral responses in a preclinical mouse model of migraine	10
Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice	10
The Adaptation of Management of Chronic Migraine Patients With Medication Overuse to the Suspension of Treatment Protocols During the COVID‐19 Pandemic: Lessons From a Tertiary Headache Center in Mila	10
Characteristics and natural disease history of persistent idiopathic facial pain, trigeminal neuralgia, and neuropathic facial pain	10
Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States	10
The role of avoiding known triggers, embracing protectors, and adhering to healthy lifestyle recommendations in migraine prophylaxis: Insights from a prospective cohort of 1125 people with episodic mi	10
Investigating the effects of weather on headache occurrence using a smartphone application and artificial intelligence: A retrospective observational cross‐sectional study	10
Impact of the COVID‐19 pandemic on people living with migraine: Results of the MiCOAS qualitative study	10
62nd Annual Scientific Meeting American Headache Society®	10
Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men	10
Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial	10
The Health and Productivity Burden of Migraines in Australia	10
Addressing the Crisis of Diagnosis and Management of Migraine in Primary Care: A Summary of the American Headache Society FrontLine Primary Care Advisory Board	9
Effectiveness of manual therapy in the treatment of cervicogenic headache: A systematic review	9
Prospective cohort study of routine exercise and headache outcomes among adults with episodic migraine	9
Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study	9
Structural aberrations of the brain associated with migraine: A narrative review	9
Understanding What People With Migraine Consider to be Important Features of Migraine Tracking: An Analysis of the Utilization of Smartphone‐Based Migraine Tracking With a Free‐Text Feature	9
Patients With Vestibular Migraine are More Likely to Have Occipital Headaches than those With Migraine Without Vestibular Symptoms	9
Are psychological interventions efficacious for adults with migraine? A systematic review and meta‐analysis	9
Dietary intake of thiamine and riboflavin in relation to severe headache or migraine: A cross‐sectional survey	9
The Role of Positive Health Behaviors in the Relationship Between Early Life Stress and Migraine	9
Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study	9
Longitudinal Impact of Parent Factors in Adolescents With Migraine and Tension‐Type Headache	9
Headache response after CT‐guided fibrin glue occlusion of CSF‐venous fistulas	9
Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment	9
Trigeminal neuralgia in children and adolescents: Experience of a tertiary pediatric headache clinic	9
A real‐world, observational study of erenumab for migraine prevention in Canadian patients	9
The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015‐2016	9
Association among headache, temporomandibular disorder, and awake bruxism: A cross‐sectional study	9
The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review	9
Different characteristics of cortical spreading depression in the sleep and wake states	8
Medication overuse headache in patients with chronic migraine using cannabis: A case–referent study	8
Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review	8
Acute and chronic management of posttraumatic headache in children: A systematic review	8
Shared biological foundations of post‐traumatic headache and migraine	8
Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity	8
Open‐Label, Multi‐Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster Headache	8
Migraine and balance impairment: Influence of subdiagnosis, otoneurological function, falls, and psychosocial factors	8
Headache Due to COVID‐19: A Disabling Combination	8
Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke‐like episodes syndrome: A case report	8
Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine	8
Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials	8
Headache Virtual Visit Toolbox: The Transition From Bedside Manners to Webside Manners	8
Impact of emergency department opioid use on future health resource utilization among patients with migraine	8
“You will eat shoe polish if you think it would help”—Familiar and lesser‐known themes identified from mixed‐methods analysis of a cluster headache survey	8
Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review	8
Primary Empty Sella	8
Later high school start time is associated with lower migraine frequency in adolescents	8
Types of Triggers in Migraine – Factor Structure of the Headache Triggers Sensitivity and Avoidance Questionnaire and Development of a New Short Form (HTSAQ‐SF)	8
Ketamine‐Magnesium for Refractory Chronic Cluster Headache: A Case Series	8
Migraine and peripheral pain models show differential alterations in neuronal complexity	8
Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses	8
Migraine treatment and COVID‐19 vaccines: No cause for concern	8
American Headache Society 64th Annual Scientific Meeting June 9–12, 2022 Denver, Colorado	8
Ten Eleven things to facilitate participation of underrepresented groups in headache medicine research	8
A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) ant	8
The Influence of Photophobia on Postural Control in Patients With Migraine	8
Cancer risk in patients with migraine: A population‐based cohort study in Denmark	7
Parkinson’s Disease and Headaches: A Cross‐Sectional Study	7
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes	7
Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache	7
The unique role of stigma in migraine‐related disability and quality of life	7
Primary headache disorders and body mass index categories: A systematic review and dose–response meta‐analysis	7
Peripheral, Interictal Serum S100B Levels are Not Increased in Chronic Migraine Patients	7
Headache persisting after aneurysmal subarachnoid hemorrhage: A narrative review of pathophysiology and therapeutic strategies	7
The role of artificial intelligence in headache medicine: Potential and peril	7
Gene polymorphism association studies in cluster headache: A field synopsis and systematic meta‐analyses	7
Spatial aspects of pain modulation are not disrupted in adolescents with migraine	7
Did she have an epidural? The long‐term consequences of postdural puncture headache and the role of unintended dural puncture	7
Migraine treatment with external concurrent occipital and trigeminal neurostimulation—A randomized controlled trial	7
Cerebral Venous Thrombosis and Subdural Collection in a Comatose Patient: Do Not Forget Intracranial Hypotension. A Case Report	7
Music Modulates Awake Bruxism in Chronic Painful Temporomandibular Disorders	7
Treatment of medication overuse headache: Effect and predictors after 1 year—A randomized controlled trial	7
Intranasal ketamine for acute cluster headache attacks—Results from a proof‐of‐concept open‐label trial	7
	7
Readability Analysis of Online Headache and Migraine Information	7
Cross‐Cultural Headache Care Within the United States: Speaking the Unspoken	7
A Randomized Sham‐Controlled Cross‐Over Study on the Short‐Term Effect of Non‐Invasive Cervical Vagus Nerve Stimulation on Spinal and Supraspinal Nociception in Healthy Subjects	7
A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management	7
Timing and durability of response to erenumab in patients with episodic migraine	7
Adverse childhood experiences and onset of migraine in Canadian adolescents: A cohort study	7
Management of Spontaneous Intracranial Hypotension During Pregnancy: A Case Series	7
Cluster headache pathophysiology: What we have learned from advanced neuroimaging	7
Headache and systemic lupus erythematosus: A narrative review	7